Protalix BioTherapeutics, Inc. (PLX) shareholders
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3050% below fair value
$3.05+0.09 (+3.04%)
Close on Nov 13, 2026Market cap $245.74MP/E 12.2Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
17.9%
14M of 81M shares
Institutional holders
102
19 new, 16 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
1 buys · 1 sales
Net bought $101.05K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kaufman Michael A Joint filing with MAK Capital Fund LP (5.80%), Mak Capital One LLC (5.80%) | 4,649,599 | 5.80% | 13G (passive) | Feb 26, 2026 |
| HOLD Alapkezelo Zrt. | 4,157,791 | 5.20% | 13G (passive) | Oct 14, 2026 |
| BlackRock, Inc. | 4,046,650 | 5.02% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PLX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,046,650 | 5.02% | $9.43M | +429,688 | 0.00% |
| Renaissance Technologies LLC | 1,096,000 | 1.36% | $2.55M | −128,800 | 0.00% |
| State Street Corp | 983,582 | 1.22% | $2.29M | +10,767 | 0.00% |
| Geode Capital Management, LLC | 979,995 | 1.22% | $2.28M | +114,697 | 0.00% |
| Northern Trust Corp | 922,340 | 1.14% | $2.15M | +36,892 | 0.00% |
| Vanguard Portfolio Management LLC | 510,639 | 0.63% | $1.19M | +78,154 | 0.00% |
| Stratos Wealth Partners, LTD. | 500,000 | 0.62% | $1.17M | – | 0.01% |
| Dimensional Fund Advisors LP | 493,424 | 0.61% | $1.15M | +196,581 | 0.00% |
| Goldman Sachs Group Inc | 475,922 | 0.59% | $1.11M | +224,577 | 0.00% |
| Marshall Wace, Llp | 452,757 | 0.56% | $1.05M | New | 0.00% |
| Citadel Advisors LLC | 334,227 | 0.41% | $778.75K | New | 0.00% |
| Strs Ohio | 296,100 | 0.37% | $689.91K | New | 0.00% |
| Bank of New York Mellon Corp | 232,992 | 0.29% | $542.87K | +13,685 | 0.00% |
| Main Street Financial Solutions, LLC | 214,100 | 0.27% | $498.85K | – | 0.03% |
| Bridgeway Capital Management, LLC | 189,100 | 0.23% | $440.60K | – | 0.01% |
| Hillsdale Investment Management Inc. | 185,711 | 0.23% | $432.71K | New | 0.01% |
| Charles Schwab Investment Management Inc | 180,381 | 0.22% | $420.29K | +21,070 | 0.00% |
| Millennium Management LLC | 171,535 | 0.21% | $399.68K | New | 0.00% |
| Aqr Capital Management LLC | 167,826 | 0.21% | $391.04K | +137,333 | 0.00% |
| Lazard Asset Management LLC | 165,561 | 0.21% | $385.76K | +78,944 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 102 | 14M | 17.9% | 19 / 38 | 17 / 16 | 3M | 6M |
| Q1 2026 | 100 | 17M | 20.9% | 27 / 28 | 20 / 9 | 6M | 3M |
| Q4 2025 | 83 | 15M | 18.5% | 12 / 28 | 23 / 5 | 2M | 1M |
| Q3 2025 | 77 | 14M | 17.3% | 17 / 18 | 20 / 3 | 4M | 2M |
| Q2 2025 | 63 | 12M | 14.8% | 30 / 20 | 3 / 30 | 8M | 4M |
| Q1 2025 | 63 | 8M | 10.2% | 23 / 19 | 10 / 5 | 4M | 1M |
| Q4 2024 | 45 | 4M | 5.5% | 8 / 12 | 9 / 8 | 1M | 0M |
| Q3 2024 | 45 | 3M | 4.3% | 7 / 5 | 19 / 27 | 1M | 3M |
| Q2 2024 | 66 | 6M | 7.0% | 27 / 12 | 16 / 23 | 3M | 7M |
| Q1 2024 | 63 | 10M | 12.1% | 8 / 17 | 20 / 11 | 1M | 1M |
| Q4 2023 | 66 | 10M | 12.6% | 12 / 22 | 16 / 7 | 2M | 1M |
| Q3 2023 | 61 | 9M | 11.4% | 9 / 26 | 12 / 14 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
75 funds held PLX in Q2 2026, 64% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PLX | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Russell 2000 ETF | 1,932,793 | 2.40% | $4.50M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 802,533 | 1.00% | $1.90M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 695,410 | 0.86% | $1.62M | 0.01% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 372,499 | 0.46% | $785.97K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 248,807 | 0.31% | $579.72K | 0.04% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 215,985 | 0.27% | $511.88K | 0.00% | Jul 31, 2026 |
| Schwab Small-Cap Index Fund | 180,314 | 0.22% | $427.34K | 0.01% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 180,000 | 0.22% | $419.40K | 0.28% | Jun 30, 2026 |
| Master Small Cap Index Series | 120,799 | 0.15% | $281.46K | 0.00% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 90,188 | 0.11% | $213.75K | 0.01% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 87,615 | 0.11% | $207.65K | 0.00% | Jul 31, 2026 |
| U.S. Small Cap Equity Fund | 80,374 | 0.10% | $190.49K | 0.02% | Jul 31, 2026 |
| WisdomTree U.S. SmallCap Fund | 78,247 | 0.10% | $182.32K | 0.03% | Jun 30, 2026 |
| EQ/2000 Managed Volatility Portfolio | 75,469 | 0.09% | $175.84K | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Growth Index Fund | 69,173 | 0.09% | $161.17K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dror Bashan | PRESIDENT AND CEO, Director | 2,532,934 | 3.14% | Sep 4, 2026 |
| Yaron Naos | Sr. VP & COO | 232,929 | 0.29% | Sep 4, 2026 |
| Gilad Mamlok | Sr. VP and CFO | 3,631 | 0.00% | Apr 27, 2026 |
| Aharon Schwartz | Director | 310,500 | 0.39% | Sep 9, 2026 |
| Pol F. Boudes | Director | 7,540 | 0.01% | Sep 4, 2026 |
| Christian Elze | Director | 7,500 | 0.01% | Sep 4, 2026 |
| Zvi Shmuel Ben | Director | 7,500 | 0.01% | Sep 4, 2026 |
| Eliot Forster | Director | 7,500 | 0.01% | Sep 4, 2026 |
| Amos Bar-Shalev | Director | 7,500 | 0.01% | Sep 4, 2026 |
| Gwen A. Melincoff | Director | 7,500 | 0.01% | Sep 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dror Bashan PRESIDENT AND CEO, Director | Dec 19, 2025 | Buy | +56,000 | $1.81 | $101.36K | 188,516 |
| Amos Bar-Shalev Director | Nov 18, 2025 | Sale | −168 | $1.87 | $314 | 0 |
| Pol F. Boudes Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Christian Elze Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Yaron Naos Sr. VP, Operations | Sep 3, 2025 | Award | +25,000 | – | – | 225,817 |
| Amos Bar-Shalev Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Aharon Schwartz Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Gwen A. Melincoff Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Zvi Shmuel Ben Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Eliot Forster Director | Sep 3, 2025 | Award | +7,500 | – | – | 7,500 |
| Dror Bashan PRESIDENT AND CEO, Director | Sep 3, 2025 | Award | +195,000 | – | – | 2,344,418 |
| Aharon Schwartz Director | Jun 10, 2025 | Buy | +129,000 | $1.60 | $206.40K | 303,000 |
| Eyal Rubin Sr. VP and CFO | Sep 23, 2024 | Award | +90,909 | – | – | 660,909 |
| Eyal Rubin Sr. VP and CFO | Sep 23, 2024 | Award | +99,010 | – | – | 669,010 |
| Dror Bashan PRESIDENT AND CEO, Director | Apr 1, 2024 | Award | +263,960 | – | – | 2,149,418 |
| Dror Bashan PRESIDENT AND CEO, Director | Oct 19, 2023 | Buy | +48,387 | $1.40 | $67.74K | 116,387 |
| Dror Bashan PRESIDENT AND CEO, Director | Oct 19, 2023 | Buy | +16,129 | $1.41 | $22.74K | 132,516 |
| Eyal Rubin Sr. VP and CFO | Aug 15, 2023 | Award | +201,903 | – | – | 570,000 |
| Dror Bashan President and CEO, Director | Aug 15, 2023 | Award | +800,000 | – | – | 1,885,458 |
| Yael Hayon VP, Research & Development | Aug 15, 2023 | Award | +35,115 | – | – | 35,115 |
| Yaron Naos Sr. VP, Operations | Aug 15, 2023 | Award | +187,344 | – | – | 200,817 |
| Aharon Schwartz Director | Jan 3, 2023 | Buy | +110,000 | $1.42 | $156.20K | 174,000 |
| Dror Bashan President and CEO, Director | Apr 11, 2022 | Buy | +68,000 | $1.50 | $102.00K | 68,000 |
| Eyal Rubin Sr. VP and CFO | Feb 25, 2022 | Award | +121,951 | – | – | 368,097 |
| Dror Bashan President and CEO, Director | Feb 25, 2022 | Award | +637,531 | – | – | 1,085,458 |
| Dan Oren 10% owner | Jun 3, 2021 | Sale | −857,506 | $2.25 | $1.93M | 3,637,314 |
| Dan Oren 10% owner | Jun 2, 2021 | Sale | −61,211 | $2.56 | $156.70K | 4,494,820 |
| Eyal Rubin Sr. VP and CFO | Aug 11, 2020 | Award | +246,146 | – | – | 246,146 |
| Dror Bashan President and CEO, Director | Aug 11, 2020 | Award | +447,927 | – | – | 447,927 |
| Eyal Rubin Sr. VP and CFO | Aug 11, 2020 | Award | +246,146 | – | – | 246,146 |
| Dror Bashan President and CEO, Director | Aug 11, 2020 | Award | +447,927 | – | – | 447,927 |
| Aharon Schwartz Director | Apr 7, 2020 | Buy | +64,000 | $2.43 | $155.52K | 64,000 |
| Moshe Manor President & CEO, Director | May 16, 2017 | Buy | +50,000 | $0.81 | $40.50K | 50,000 |
| Capital Management LLC Camber 10% owner | Dec 2, 2016 | Sale | −2,500,000 | $0.32 | $800.00K | 10,775,000 |
| Yoseph Shaaltiel Executive VP, R&D | Sep 15, 2016 | Option exercise | +122,162 | – | – | 585,916 |
| Yossi Maimon Vice President & CFO | Dec 14, 2015 | Buy | +10,000 | $0.78 | $7.80K | 10,000 |
| Capital Management LLC Camber 10% owner | Oct 19, 2015 | Buy | +423 | $1.03 | $436 | 13,275,000 |
| Capital Management LLC Camber 10% owner | Oct 19, 2015 | Buy | +4,000,000 | $1.00 | $4.00M | 13,274,577 |
| Zeev Bronfeld Director | Oct 2, 2014 | Other | +324,372 | – | – | 2,162,481 |
| Zeev Bronfeld Director | Oct 2, 2014 | Other | −1,509,948 | – | – | 0 |
| Zeev Bronfeld Director | Sep 16, 2014 | Other | +1,838,109 | – | – | 1,838,109 |
| Zeev Bronfeld Director | Sep 16, 2014 | Other | −8,556,371 | – | – | 1,509,948 |
| Ltd Bio-Cell 10% owner | Sep 16, 2014 | Other | −8,556,371 | – | – | 1,509,948 |
| Ltd Bio-Cell 10% owner | Aug 13, 2014 | Sale | −4,400,000 | $2.47 | $10.87M | 10,066,319 |
| Zeev Bronfeld Director, 10% owner | Aug 13, 2014 | Sale | −4,400,000 | $2.47 | $10.87M | 10,066,319 |
| Alfred Akirov Director | Aug 15, 2013 | Sale | −2,330 | $5.07 | $11.81K | 4,915,383 |
| Alfred Akirov Director | Aug 14, 2013 | Sale | −5,000 | $5.08 | $25.40K | 4,917,713 |
| Alfred Akirov Director | Aug 14, 2013 | Sale | −100,000 | $5.05 | $505.00K | 4,927,713 |
| Alfred Akirov Director | Aug 14, 2013 | Sale | −5,000 | $5.07 | $25.35K | 4,922,713 |
| Alfred Akirov Director | Mar 12, 2013 | Sale | −10,000 | $5.70 | $57.00K | 5,027,713 |
| Alfred Akirov Director | Mar 11, 2013 | Sale | −10,000 | $5.72 | $57.20K | 5,042,713 |
| Alfred Akirov Director | Mar 11, 2013 | Sale | −3,000 | $5.75 | $17.25K | 5,052,713 |
| Alfred Akirov Director | Mar 11, 2013 | Sale | −300 | $5.79 | $1.74K | 5,055,713 |
| Alfred Akirov Director | Mar 11, 2013 | Sale | −5,000 | $5.71 | $28.55K | 5,037,711 |
| Alfred Akirov Director | Mar 8, 2013 | Sale | −1,898 | $5.95 | $11.29K | 5,056,013 |
| Alfred Akirov Director | Mar 8, 2013 | Sale | −2,500 | $5.92 | $14.80K | 5,057,911 |
| Alfred Akirov Director | Mar 8, 2013 | Sale | −2,500 | $5.91 | $14.78K | 5,060,411 |
| Alfred Akirov Director | Mar 8, 2013 | Sale | −10,000 | $5.82 | $58.20K | 5,062,911 |
| Alfred Akirov Director | Mar 7, 2013 | Sale | −3,435 | $5.73 | $19.68K | 5,072,911 |
| Alfred Akirov Director | Mar 7, 2013 | Sale | −5,000 | $5.71 | $28.55K | 5,076,346 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
4.49%
3M shares short
Days to cover
6.2
At 1M shares a day
Change since last report
-0.8%
From 4M shares
Short volume, 20 days
36.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Protalix BioTherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,627 shares on Sep 14, 2026 over the last 90 days.
See a number that looks wrong?